Patents Examined by Larry R. Helms
  • Anti-EGFR antibodies
    Patent number: 7723484
    Abstract: The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: May 25, 2010
    Assignee: Applied Molecular Evolution, Inc.
    Inventors: Catherine Brautigam Beidler, Alain Philippe Vasserot, Jeffry Dean Watkins
  • Compositions and methods for treating cancer
    Patent number: 7723292
    Abstract: An improved more comprehensive understanding of tumors is disclosed including a precise molecular etiology leading to tumor cell growth. The disclosed molecular etiology explains the lack of control of tumor cell growth as well as the activation of a variety of phenotypic and pathological molecular mechanisms that are the natural result of the disclosed tumor etiology. A comprehensive approach to the detection and treatment of neoplasia is also disclosed.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 25, 2010
    Assignee: Fernando and Anna Foundation
    Inventors: Fernando Ferretti, Anna Ferretti
  • Preventives/remedies for cancer
    Patent number: 7723496
    Abstract: A compound inhibiting the activity of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 25 or SEQ ID NO: 27, or a salt thereof; a compound inhibiting the expression of a gene of the protein; an antisense polynucleotide containing the entire or part of a base sequence complementary or substantially complementary to a base sequence of a polynucleotide encoding the protein or its partial peptide; an antibody to the protein or its partial peptide, etc. are useful as prophylactic/therapeutic agents for cancer, etc., apoptosis promoters for cancer cells, and the like.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: May 25, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takafumi Ishii, Koji Yamamoto, Eiji Sunahara, Shuji Sato
  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
    Patent number: 7723485
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 25, 2010
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
    Patent number: 7714119
    Abstract: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: May 11, 2010
    Assignee: Biosante Pharmaceuticals, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Jing Jing Qian
  • Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
    Patent number: 7714109
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: May 11, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Xianming Huang, Sophia Ran
  • Method of producing an HIV-1 immune response
    Patent number: 7709003
    Abstract: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: May 4, 2010
    Assignee: Bionor Immuno AS
    Inventor: Birger Sörensen
  • Method of producing an HIV-1 immune response
    Patent number: 7709004
    Abstract: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: May 4, 2010
    Assignee: Bionor Immuno AS
    Inventor: Birger Sörensen
  • Anticancer vaccine and diagnostic methods and reagents
    Patent number: 7704507
    Abstract: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 27, 2010
    Assignees: University of Pittsburgh - of the Commonwealth System of Higher Education, University of Virginia Patent Foundation
    Inventors: Olivera J. Finn, Henry Kao, Donald F. Hunt, Jarrod A. Marto
  • Nucleic acid and corresponding protein entitled 205P1B5 useful in treatment and detection of cancer
    Patent number: 7700749
    Abstract: A novel gene (designated 205P1B5) and its encoded protein are described. While 205P1B5 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostrate cancer. Consequently, 205P1B5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 205P1B5 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 20, 2010
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Aya Jakobovits
  • Method of diagnosis and treatment and agents useful for same
    Patent number: 7700271
    Abstract: The present invention relates generally to a method for detecting an aberrant cell, and more particularly an aberrant epithelial cell, in a subject or in a biological sample from said subject and agents useful for same. More particularly, the present invention relates to a method of deleting an aberrant mammary epithelial cell. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: April 20, 2010
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Jane Ellen Visvader, Geoffrey John Lindeman, Eleanor Y. M. Sum, Lorraine Ann O'Reilly
  • Humanized antibodies that recognize ?-amyloid peptide
    Patent number: 7700751
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: April 20, 2010
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Function and regulation of ADAMTS-1
    Patent number: 7696307
    Abstract: The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: April 13, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Qin Yu
  • Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
    Patent number: 7696320
    Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: April 13, 2010
    Assignee: Domantis Limited
    Inventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M. T. de Wildt
  • Viral vectors expressing fusion of viral large envelope protein and protein of interest
    Patent number: 7678374
    Abstract: The present invention provides a virus-like particle (VLP) comprising i) a polypeptide comprising a polypeptide of interest (POI) and at least a particle-associating portion of a large envelope (L) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof. By introducing one or more POIs into the L polypeptide, the POI is translocated along with L into a particle structure made up primarily of S polypeptide. The present invention furthermore provides methods for producing a recombinant virus-like particle.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: March 16, 2010
    Assignee: Hepgenics Pty Ltd
    Inventors: David Andrew Anderson, Elizabeth Vera Ludmila Grgacic
  • Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
    Patent number: 7670604
    Abstract: Disclosed are methods for treating or preventing a neoplastic or a multidrug resistant neoplasm in a subject using cell surface vimentin targeted therapeutic agents.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: March 2, 2010
    Assignee: Aurelium Biopharma, Inc.
    Inventors: Elias Georges, Lucile Serfass, Anne-Marie Bonneau, Frédéric Dallaire
  • Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
    Patent number: 7671010
    Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11R? and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: March 2, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Wadih Arap, Mikhail G. Kolonin, Paul J. Mintz, Renata Pasqualini, Amado J. Zurita
  • Breast homing peptides and methods of identifying same using aminopeptidase P
    Patent number: 7666391
    Abstract: The present invention provides a method of directing a moiety to breast vasculature in a subject by administering to the subject a conjugate which contains a moiety linked to a homing molecule that selectively homes to breast vasculature, whereby the moiety is directed to breast vasculature. In one embodiment, the homing molecule is a peptide containing the amino acid sequence PGPEGAG (SEQ ID NO: 1), or a peptidomimetic thereof.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: February 23, 2010
    Assignee: Burnham Institute for Medical Research
    Inventors: Erkki Ruoslahti, Markus Essler
  • Modified soluble T cell receptor
    Patent number: 7666604
    Abstract: The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR $g(a) chain, except the transmembrane domain thereof, and (ii) all or part of a TCR $g(b) chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR, characterized in that the sTCR recognizes a CD1-antigen complex, a bacterial superantigen or a peptide-MHC/superantigen complex.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: February 23, 2010
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Meir Glick
  • Methods for the treatment of neoplastic disorders with anti-caveolin agents
    Patent number: 7666412
    Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: February 23, 2010
    Assignee: Baylor College of Medicine
    Inventor: Timothy C. Thompson